Lille Cedex

• Phase 1b study investigating the association of NP137 with mFOLFIRINOX in locally advanced pancreatic ductal adenocarcinoma LAP NET 1 Ended
  2022-500905-42-00 3 2023-03-24 pancreatic ductal adenocarcinoma
• C4951004 - BHV3000-406: A Phase 4, Randomized, Double-blind Placebo Controlled, Efficacy and Tolerability Trial of Rimegepant for the Acute … Ended
  2024-513269-37-00 6 2023-03-14 Migraine attacks with or without aura
• A Open-label Study to Evaluate the Efficacy, Safety, Tolerability of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis Ended
  2023-509783-23-00 4 2023-02-24 Diffuse Cutaneous Systemic Sclerosis
• A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Assess the Efficacy, Safety, Tolerability, PK, and Biomarker Effe … Ended
  2023-510317-26-00 4 2023-02-07 Amyotrophic Lateral Sclerosis
• A study to test asundexian for preventing a stroke caused by a clot in participants after an acute ischemic stroke or after a high-risk tran … Ended
  2023-503793-20-00 5 2023-01-18 Prevention of ischemic stroke in patients post acute non-cardioembolic
• Phase 3 Study of Bepirovirsen in Nucleos(t)ide Analogue-treated Participants with Chronic Hepatitis B (B-Well 1) Ended
  2023-504239-41-00 5 2023-01-09 Hepatitis B, Chronic
• Clinical study to show if Naronapride tablets are safe and efficient for treatment of delayed stomach emptying and to find the optimal dose. Ended
  2023-510195-31-00 4 2023-01-03 Idiopathic or Diabetic Gastroparesis
• Glenzocimab for REperfusion in the setting of Endovascular therapy for brain infarctioN Ended
  2024-514352-32-00 10 2023-01-03 Acute ischemic stroke
• An extension of the orchestra (PD0053) study to learn how safe minzasolmin is and if it works long-term in participants with Parkinson’s dis … Ended
  2022-500424-30-00 4 2022-12-28 Parkinson’s disease
• Ezurpimtrostat autophagy inhibitor in association with Atezolizumab-Bevacizumab in first line treatment of unresectable hepatocellular carci … Ended
  2022-502078-17-00 4 2022-12-15 unresectable hepatocellular carcinoma
• Caplacizumab and immunosuppressive therapy without first-line therapeutic plasma exchange in adults with immune-mediated thrombotic thrombo … Ended
  2024-513262-19-00 5 2022-11-21 Thrombotic Thrombocytopenic Purpura
• A long-term study to evaluate if KVD900 is safe and effective in treating attacks in patients with Hereditary Angioedema. Ended
  2023-505904-41-00 5 2022-11-17 Hereditary Angioedema Type I or II
• MYOCIT - Baricitinib in the treatment of new-onset juvenile dermatomyositis: a phase II trial Ended
  2024-513651-32-00 4 2022-11-10 Juvenile Dermatomyositis
• A Phase 2 Study of LTX-315 in Combination with Pembrolizumab in Patients with Advanced Melanoma Refractory to PD-1/PD-L1 Inhibitor Therapy ( … Ended
  2022-500628-31-00 4 2022-10-24 Advanced Melanoma
• A Phase 3 Study of Itolizumab in Combination with Corticosteroids for the Initial Treatment of Acute Graft Versus Host Disease (Complication … Ended
  2024-516064-28-00 5 2022-09-27 Acute Graft Versus Host Disease
• Bemarituzumab plus Chemotherapy and Nivolumab versus Chemotherapy and Nivolumab Alone (FORTITUDE-102) Ended
  2023-505458-16-00 5 2022-09-13 Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpressio
• A Study of Eptinezumab in Participants With Migraine and Medication Overuse Headache Ended
  2024-510729-24-00 6 2022-09-01 Chronic Migrane, Migrane, Medication Overuse Headache
• Efficacy and Safety of AXL-Inhibitor bemcentinib for the Treatment of Moderate COVID-19 (AXL-SolidAct) Ended
  2022-500363-12-00 4 2022-08-24 SARS CoV-2 (COVID-19)
• Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Ended
  2022-502773-41-00 9 2022-06-16 Relapsed/Refractory Classical Hodgkin Lymphoma
• Iron chelation in the prevention of secondary degeneration after stroke Ended
  2024-514230-20-00 4 2022-06-08 Stroke
• IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma Ended
  2024-511996-13-00 5 2022-05-11 Previously untreated, unresectable, or metastatic melanoma
• N/A Ended
  2024-515090-96-00 11 2022-05-10 Thyroid Eye Disease
• Treatment of non severe Hemophagocytosis Lymphohistiocytosis with ITACITINIB a Phase II prospective trial Ended
  2024-513173-44-00 4 2022-05-03 Adults patients having non severe HLH
• Open-label extesnion study of soticlestat in Dravet and Lennox-Gastaut Syndromes Ended
  2022-502802-34-00 5 2022-04-05 Dravet and Lennox-Gastaut Syndromes

Showing 601–624 of 681 trials